A week, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of Fingerroot(Bosenbergia pandurata) 300mg and 600mg on reducing body weight and body fat of obese subjects

ewtree0 个研究点目标入组 150 人开始时间: 待定最近更新: 2019年3月11日

试验速览

暂无简介。

•1) Male and female subjects between 20-65years of age inclusive.
•2) BMI of 25.0-29.9kg/m2
•3) Evidense of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.

•1. Subjects with systolicBP = 160 mmHg or diastolicBP = 100 mmHg and also taking a beta blocker or a hydragogue.
•2. Subjects with diabetes(use of hypoglycemic agent or insulin)or fasting blood glucose = 126 mg/dL or random blood glucose = 200 mg/dL.
•3. Subjects with endocrinopathy or abnormal screening TSH value(=0.1uU/ml or =10 uU/ml).
•4. Serum AST/ALT = 3 times the upper limit of normal.
•5. Serum creatinine = 2 times the upper limit of normal.
•6. Use of prescription drugs or supplements known to alter body weight or appetite, antidepressants, oral contraceptive, steroid, female sex hormon.
•7. Subjets with clinically significant cardiovascular disease within the 6 months prior to screening.
•8. Subjets with a history of cancer and intervention within the 5 years prior to screening.
•9. Subjects with a history of CNS disorder(depressivedisorder,schizophrenia, alcoholism, drug addiction).
•10. Women of childbearing age who are disagreed with effective contraceptions in the clinical trial period.
•11. Woman who are pregnant or lactating.
•12. Participation in any clinical trial within the 3 months prior to screening.
•13. Subjects with bleeding risk factor of stomach.
•14. Subjects with the musculoskeletal disorders or restricted physical activity.
•15. Subjects who could affect preclude evauation of response in the opinion investigator.

发起方

ewtree